I haven't seen anyone touch on this out of the Corporate Presentation, but there could be data released to the market in February, March and April.
Upcoming Data 2020 (est):
1. NSCLC 1st line - more data from Stages 1 and 2 from TACTI002 throughout 2020 (e.g. German Cancer Congress February 2020)
2. MBC - mature, robust PFS & ORR data from AIPAC: Q12020 (March)
3. HNSCC 2nd line - initial data from Stages 1 and 2 fromTACTI-002 throughout 2020 (e.g. AACR April 2020)
If all positive, then surely a long awaited rerating of the SP will occur!
Ann: Immutep Corporate Presentation, page-60
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73996 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 836970 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |